Skip to main content
. 2017 Jan 10;37(2):737–746. doi: 10.3892/or.2017.5362

Figure 3.

Figure 3.

Secretion of (A) matrix metalloproteinase (MMP)-9 and (B) nuclear factor-κB (NF-κB) p65 activity in peripheral blood mononuclear cells (PBMCs) from healthy donors and melanoma cases following treatment with recombinant human osteopontin (rhOPN). The levels of both (A) MMP-9 and (B) NF-κB p65 activity were higher in patients with melanoma than in the controls. *P<0.05 compared to the rhOPN-treated cells. OD, optical density.